The recent full approval of Leqembi (lecanemab-irmb) has upped the stakes for what promises to be a particularly intriguing congress of the Alzheimer’s Associat 12 July 2023
Spanish skincare specialist Almirall has announced positive results from a real-world study of Ilumetri (tildrakizumab) at the 25th World Congress of Dermatolog 7 July 2023
Eisai has broken new ground in the development of Alzheimer's treatments, gaining the first approval for decades. In the runup to AAIC 2023, we discuss progress 6 July 2023
In the USA, people with the most severe form of hepatitis have reason to cheer as Gilead Sciences announces new positive data at the annual congress of the Euro 23 June 2023
Privately-held Californian firm Alladapt Immunotherapeutics has announced topline results from the Phase I/II Harmony study of its multi-targeted allergy treatm 14 June 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.